184 related articles for article (PubMed ID: 35956764)
21. MALDI-TOF-MS Analysis in the Discovery and Identification of the Serum Peptide Pattern of Pancreatic Ductal Adenocarcinoma.
Huang Y; Chen F; Zhang L; Lv Q; Yan J; Cui W
Lab Med; 2021 Nov; 52(6):558-566. PubMed ID: 33929035
[TBL] [Abstract][Full Text] [Related]
22. Quantitative proteomic profiling identifies DPYSL3 as pancreatic ductal adenocarcinoma-associated molecule that regulates cell adhesion and migration by stabilization of focal adhesion complex.
Kawahara T; Hotta N; Ozawa Y; Kato S; Kano K; Yokoyama Y; Nagino M; Takahashi T; Yanagisawa K
PLoS One; 2013; 8(12):e79654. PubMed ID: 24339867
[TBL] [Abstract][Full Text] [Related]
23. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.
Rebours V; Le Faouder J; Laouirem S; Mebarki M; Albuquerque M; Camadro JM; Léger T; Ruszniewski P; Lévy P; Paradis V; Bedossa P; Couvelard A
Pancreatology; 2014; 14(2):117-24. PubMed ID: 24650966
[TBL] [Abstract][Full Text] [Related]
24. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
25. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
26. Glycoproteins and glycoproteomics in pancreatic cancer.
Pan S; Brentnall TA; Chen R
World J Gastroenterol; 2016 Nov; 22(42):9288-9299. PubMed ID: 27895417
[TBL] [Abstract][Full Text] [Related]
27. Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas.
Corcos O; Couvelard A; Dargère D; Sauvanet A; Hammel P; Paradis V; Lévy P; Ruszniewski P; Bedossa P
Pancreas; 2012 Mar; 41(2):169-74. PubMed ID: 22076567
[TBL] [Abstract][Full Text] [Related]
28. Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma.
Chen J; Chen LJ; Xia YL; Zhou HC; Yang RB; Wu W; Lu Y; Hu LW; Zhao Y
J Cancer Res Clin Oncol; 2013 Jul; 139(7):1117-27. PubMed ID: 23546595
[TBL] [Abstract][Full Text] [Related]
29. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging.
Ucal Y; Tokat F; Duren M; Ince U; Ozpinar A
Thyroid; 2019 Aug; 29(8):1125-1137. PubMed ID: 31064269
[No Abstract] [Full Text] [Related]
30. The clinicopathological significance of forkhead box P1 and forkhead box O3a in pancreatic ductal adenocarcinomas.
Luo X; Yang Z; Liu X; Liu Z; Miao X; Li D; Zou Q; Yuan Y
Tumour Biol; 2017 May; 39(5):1010428317699129. PubMed ID: 28466777
[TBL] [Abstract][Full Text] [Related]
31. [MALDI imaging mass spectrometry for direct tissue analysis].
Rauser S; Höfler H; Walch A
Pathologe; 2009 Dec; 30 Suppl 2():140-5. PubMed ID: 19756619
[TBL] [Abstract][Full Text] [Related]
32. Proteomic analysis of pancreatic ductal adenocarcinoma.
Meleady P; Abdul Rahman R; Henry M; Moriarty M; Clynes M
Expert Rev Proteomics; 2020 Jun; 17(6):453-467. PubMed ID: 32755290
[TBL] [Abstract][Full Text] [Related]
33. Identification of Small Proteins and Peptides in the Differentiation of Patients with Intraductal Mucinous Neoplasms of the Pancreas, Chronic Pancreatitis and Pancreatic Adenocarcinoma.
Fania C; Pezzilli R; Melzi d'Eril G; Gelfi C; Barassi A
Dig Dis Sci; 2018 Apr; 63(4):920-933. PubMed ID: 29417328
[TBL] [Abstract][Full Text] [Related]
34. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
Chung JC; Oh MJ; Choi SH; Bae CD
ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
[TBL] [Abstract][Full Text] [Related]
35. Potential prognostic biomarkers of pancreatic cancer.
Chen KT; Kim PD; Jones KA; Devarajan K; Patel BB; Hoffman JP; Ehya H; Huang M; Watson JC; Tokar JL; Yeung AT
Pancreas; 2014 Jan; 43(1):22-7. PubMed ID: 24326364
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
[TBL] [Abstract][Full Text] [Related]
39. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A.
Cecconi D; Scarpa A; Donadelli M; Palmieri M; Hamdan M; Astner H; Righetti PG
Electrophoresis; 2003 Jun; 24(11):1871-8. PubMed ID: 12783462
[TBL] [Abstract][Full Text] [Related]
40. [Expression and clinical significance of AHSG and complement C3 in pancreatic ductal adenocarcinoma].
Chen J; Wu W; Chen L; Ma X; Zhao Y; Zhou H; Yang R; Hu L
Zhonghua Yi Xue Za Zhi; 2014 Jul; 94(28):2175-9. PubMed ID: 25331466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
